Neramexane

DB04926InvestigationalSmall molecule

Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

Chemical structure of Neramexane
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in alzheimer's disease, hearing loss, and pain (acute or chronic).Curator reviewed
Formula / weight
C11H23N · 169.307 g/mol (avg)

Resolves to

Compound
UNII856DX0KJ84CAS219810-59-0ChEMBLCHEMBL2110954PubChem6433106
Structure
InChIKeyOGZQTTHDGQBLBT-UHFFFAOYSA-NSMILESCC1(C)CC(C)(C)CC(C)(N)C1
Targets
Q8TCU5GRIN3A

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Neramexane, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In